Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Manufacturing
  • Cellares and Sonoma partner to automate cell therapy manufacturing
  • Manufacturing

Cellares and Sonoma partner to automate cell therapy manufacturing

Pharmaceutical Technology

Cellares and Sonoma Biotherapeutics have partnered to automate the manufacturing of the latter's SBT-77-7101 programme using the Cellares Cell Shuttle platform.

Gene Therapy Platform

Read full story

pharminent July 14, 2026 (Last updated: July 15, 2026)

Pharmaceutical Technology

Cellares and Sonoma Biotherapeutics have partnered to automate the manufacturing of the latter’s SBT-77-7101 programme using the Cellares Cell Shuttle platform.

Gene Therapy Platform

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Mahzi Lets Rare-Disease Families Invest in Its Gene Therapy
Next: FDA clears at-home start dose for Alzheimer’s drug Leqembi

Related Stories

  • Manufacturing

AsymBio to secure $184m to support growth in biologics manufacturing

pharminent August 5, 2026
  • Manufacturing

Lilly and Resilience invest $750M in diabetes and obesity drug device supply

pharminent July 31, 2026
  • Manufacturing

GSK Cambridge Move Signals Shift in Drug Scale-Up Strategy

pharminent July 29, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.